Treatment of IgA nephropathy

Journal of Nephrology

Volumn 29, Issue 1, 2016, Pages 21-25

  Pozzi, Claudio ^a  

^a Bassini Hospital   (Italy)

Author keywords

Adverse events; Azathioprine; Chronic kidney disease; Corticosteroids; IgA nephropathy; RAS blockers

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; AZATHIOPRINE; BENAZEPRIL; BUDESONIDE; CREATININE; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENDOTHELIN RECEPTOR ANTAGONIST; FOSTAMATINIB; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLATE MOFETIL; OMEGA 3 FATTY ACID; PHENYTOIN; PREDNISONE; RAMIPRIL; RAPAMYCIN; RITUXIMAB; UNINDEXED DRUG; WARFARIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CORTICOSTEROID;

CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TONSILLECTOMY; VASCULITIS; CLINICAL PATHWAY; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; GLOMERULONEPHRITIS, IGA; HEMODIALYSIS; KIDNEY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CRITICAL PATHWAYS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HEMATURIA; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; PROTEINURIA; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84961305455     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0248-3     Document Type: Review

References (19)

1. KDIGO clinical practice guidelines for glomerulonephritis (2012) Chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2:S209–S217
2. Berger J, Hinglais N (1968) Le depots intercapillaire d’IgA-IgG. J Urol Nephrol 74:694–695
3. Chauveau D, Droz D (1993) Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 104:1–5
4. Appel GB (2006) To treat or not to treat IgA nephropathy? That is the question! Clin J Am Soc Nephrol 1:347–348
5. Coppo R, Peruzzi L, Amore A et al (2007) IgACE: a placebo controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888
6. Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883–887
7. Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15(1):157–163
8. Lv J, Zhang H, Chen Y et al (2009) Combination therapy of prednisolone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53:26–32
9. Manno C, Torres DD, Rossini M et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694–3701
10. Ballardie FW, Roberts ISD (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148
11. Tang SCW, Tang AWC, Wong SSH et al (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77(6):543–549
12. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21(10):1783–1790
13. Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi GB, Pecchini P, Del Vecchio L, Rustichelli R, Semeraro L, Locatelli F (2013) IgA nephropathy with severe chronic renal failure: a randomized controller trial with corticosteroids and azathioprine. J Nephrol 26:86–93
14. Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2015) Changes in proteinuria and side effects of steroids alone or in combination with azathioprine at different stages of IgA nephropathy (submitted)
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
16. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(Suppl 1):S1–S246
17. Reich HN, Troyanov S, Scholey JW, Cattran D, For the Toronto Glomerulonephritis Registry (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183
18. Sarcina C, Tinelli C, Ferrario F, Visciano B, Pani A, De Silvestri A, Fogazzi GB, Del Vecchio L, Terraneo V, Furiani S, Santagostino G, Corghi E, Pozzi C (2015) Corticosteroid treatment influences TA-proteinuria and renal survival in IgA nephropathy (submitted)
19. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts ISD, Cattran D, Coppo R, On behalf of the VALIGA Study of ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 26:2248–2258